This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Current Discounted Rates End In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Karyn O'Neil, PhD
Chief Scientific Officer at Ar­o Biotherapeutics

Profile

Karyn O’Neil is the CSO, Aro Biotherapeutics. She was previously the Venture Leader for Centyrex, a J&J Venture focused on designed protein nucleic acid conjugate technologies. She is a co-inventor on the Centyrin patents, and has led the team focused on advancing the Centyrin platform since its inception. Karyn’s team is applying protein engineering, nucleic acid chemistry and chemical conjugation technologies to enable Centyrin – mediated intracellular delivery of nucleic acid cargos in a cell specific manner.  Karyn joined Centocor/J&J in 2001 where, prior to working on Centyrins, she held positions of increasing responsibility, ultimately becoming a Director of Antibody Therapeutics.  There she played a leadership role in the discovery & optimization of multiple clinical candidates.  Prior to J&J, Karyn was in the Applied Biotechnologies group at DuPont Pharmaceuticals.  Karyn received her PhD from the University of Pennsylvania where she focused on protein engineering and protein biophysics.  She has over 55 publications, is an inventor on more than 30 patents and serves as an editor for Protein Engineering, Design and Selection.

Agenda Sessions

  • Extra-hepatic Delivery of Centyrin-targeted siRNA Conjugates

    11:45am